Trader of equities and options for over 12 years. Proprietary trading strategy involving options and biotech with a very high win to loss ratio. SMID cap biotech. Passionate about science and cooking. "Win or lose, everybody gets what they want out of the market. Some people seem to like to lose, so they win by losing money."Ed Seykota
Edward Roche is the President of Freedom Mountain Investments (http://www.freedommount.com/), an investment firm founded in 2006, located in Paoli, Pennsylvania. Freedom Mountain specializes in identifying hidden value in small and mid size companies before they are recognized by the market. The investment approach is based upon fundamental analysis and places a high emphasis on real and rising financials including sales and earnings. One special approach used to identify a catalyst for release of value is the “Venerable Owner” strategy. This strategy tracks all companies where an older owner owns 40% or more of a company. These situations often lead to sale of the company at a significant premium to market value when the owner seeks to retire. Edward Roche received a Ph. D. degree in Polymer Science and Engineering from the University of Massachusetts and earned an MBA in Finance from the Haub School of Business, St. Joseph’s University, Philadelphia PA. He recently completed a career at the McNeil division of Johnson & Johnson that included high level positions in Business Development and R&D. He is the inventor on 15 US patents in the area of drug delivery and has authored ten scientific publications.
As Head of Global Investment Research for Alhambra Investment Partners, Jeff spearheads the investment research efforts while providing close contact to Alhambra’s client base.
Jeff joined Atlantic Capital Management, Inc., in Buffalo, NY, as an intern while completing studies at Canisius College. After graduating in 1996 with a Bachelor’s degree in Finance, Jeff took over the operations of that firm while adding to the portfolio management and stock research process.
In 2000, Jeff moved to West Palm Beach to join Tom Nolan with Atlantic Capital Management of Florida, Inc. During the early part of the 2000′s he began to develop the research capability that ACM is known for. As part of the portfolio management team, Jeff was an integral part in growing ACM and building the comprehensive research/management services, and then turning that investment research into outstanding investment performance.
As part of that research effort, Jeff authored and published numerous in-depth investment reports that ran contrary to established opinion. In the nearly year and a half run-up to the panic in 2008, Jeff analyzed and reported on the deteriorating state of the economy and markets. In early 2009, while conventional wisdom focused on near-perpetual gloom, his next series of reports provided insight into the formative ending process of the economic contraction and a comprehensive review of factors that were leading to the market’s resurrection.
In 2012, after the merger between ACM and Alhambra Investment Partners, Jeff came on board Alhambra as Head of Global Investment Research.
Currently, Jeff is published nationally at RealClearMarkets, ZeroHedge, Minyanville and Yahoo!Finance.
Jeff holds a FINRA Series 65 Investment Advisor License.
I am a Ph.D. level scientist at a major pharmaceutical company. Previously I was an NIH Cancer Postdoctoral fellow at UPENN. Through my extensive research background, I am able to quickly decipher clinical information and act on it. I specialize in analyzing and trading biotech/healthcare stocks both long and short. I maintain a few core positions and trade clinical events based on extensive research to realize large percentage gains. I am open to opportunities in consulting for financial firms or local advisors. Please contact me if you are interested.
I worked for many years in management in the health care industry in the UK, in Bermuda, and for the last 20 years in Florida. The day I turned 59 1/2 I just got out of bed and decided I didn't want to work any more and that I would just take my various pensions from different countries, such as they were, roll them all into one big IRA, and just see if I could live by my wits. My investment objective is, therefore, to make enough so that I never have to work again, although it would be easy for me to do so if I wanted.
I could probably get by very well with a 10% annual yield on my capital, but of course more is more and much more is much more.
When I started out investing in stocks, I really didn't know what I was doing, but I had the occasional bit of luck, like investing every penny I had in BP in the summer of 2010, just when it couldn't go any lower. And it didn't. Then again I staked every dime I had on out of the money options on a drug that had a PDUFA date in January 2011. It was approved. Phew! But I was a nervous wreck and figured there had to be a better way.
Then about a year ago I started to study the whole business of options strategies, got myself a few books, and found out that you could sell options as well as buy them. This was a bit of a revelation, to say the least, because I had noticed that whenever I thought a stock would go up, it went down,and when I thought it would go down, it usually went up, but by selling options you could let other people's optimism work for you.
Then I found out about volatility. I had always known that the whole game was rigged, but now I began to understand how and why
I'm hoping that with some blog posts or articles here I can inform others about some of the things that I have learned in my time as a full time investor and personal hedge fund manager (O.K., layabout) so that they can avoid some basic errors, and I hope to attract enough criticism to be able to learn from those who know much more than me.
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage.
The purpose of this profile is to allow us to share with our readers new transcript-related developments.
SA Transcripts Team
Steven H. Goldman is a commercial litigation lawyer and senior partner in the Toronto law firm of Goldman Hine LLP. Steven graduated with a B.A., President's Medal recipient (1976, Carleton University, Ottawa, Ontario) and J.D. (1980, Queen's University, Kingston, Ontario). He is a former member of the board of directors of Tribute Pharmaceuticals Inc., a Canadian public pharmaceutical company which recently merged with Pozen Pharmaceuticals on February 5, 2016, and now known as Aralez Pharmaceuticals (Nasdaq: ARLZ), and a former member of the board of directors of Select Sands Corp. (TSX.Venture: SNS.V), having resigned from the board on December 21, 2016. He is currently a member of the board of directors of Comstock Metals Ltd. (TSX.V: CSL.V) which trade on the TSX Venture exchange, and member of the Executive of the Ontario Bar Association, Franchise Law Section. Steven was President & CEO of Speedy AutoService and Minute Muffer from December 2007 to December 31, 2009 (with approximately 160 locations across Canada).
Tech Analyst and opportunistic investor focused primarily on micro caps and up and coming technology companies. I am currently in discussions with a partner to develop and launch a investment premium newsletter website. If you are interested in learning more about my premium newsletter or would like to be added to my mailing list you can inbox me.
You can follow my personal trades and invest your own money with me via Instavest www.instavest.com My focus is on ground breaking technology and the companies that will deliver them in the future. I have managed a family portfolio since 2008 that has been focused on growth and income generation. You can follow me on twitter @MattMargolis24
As I said:
I discovered the Gospel in July 1979. It is worth trillions of economic dollars. It should be classified as "top secret" by the CIA. I should be awarded the Nobel Prize in economics.
A prior post.:
"John, the #'s (which represent AD), for the 3rd qtr. are 2x that of the 2nd qtr. And that's without extrapolation and assuming Vt remains constant (& Vt will rise). - 20 Jul 2016, 06:50 PM
Dr. Leland Pritchard (Ph.D, Economics, Chicago School -1933,MS, Statistics):
"You have a predictive device nobody has hit on yet" - 9/8/81
And “considering the distortions in the def. of M1a and the rapid increase in the currency component, the correlation of the time series is remarkable”
Today's BEA release: Real gross domestic product increased at an annual rate of 3.5 percent in the third quarter of 2016 (table 1), according to the "third" estimate released by the Bureau of Economic Analysis. In the second quarter, real GDP increased 1.4 percent.
I am going to change the world.
- Michel de Nostredame
In Cambridge economist, Alfred Marshall's "motives" for holding cash balances, or in this case not holding cash balances, the EXPECTATION, of a rise in the prices of things will induce a decrease in the demand for money (increase in Vt). It deals with the uncertainty which affects economic behavior, it "bridges the gaps of transition periods".
After having been in the investing world for more than 25 years from private banking and investment management to private and venture capital; I have pretty much "been there and done that" at one point or another. I am currently a silent partner for an RIA in Houston, Texas.
The majority of my time is spent analyzing, researching and writing commentary about investing, investor psychology and macro-views of the markets and the economy. My thoughts are not generally mainstream and are often contrarian in nature but I try an use a common sense approach, clear explanations and my “real world” experience in the process.
I am the Chief Editor of the REAL INVESTMENT REPORT, a weekly subscriber based-newsletter that is distributed nationwide. The newsletter covers economic, political and market topics as they relate to your money and life.
I also write a daily blog which is read by thousands nationwide from individuals to professionals at www.realinvestmentadvice.com.
The Oil & Gas Investments Bulletin (http://www.oilandgas-investments.com) is an online subscription-based service that finds, researches, and profiles growing oil and gas companies that have high growth rates (or high growth potential.)
Its team of writers work under Keith Schaefer, Editor/Publisher, who shares his knowledge of the oil and natural gas markets in a simple, easy to read manner. The bulletin outlines which TSX, NYSE and NASD-listed energy companies have the ability to grow, and bring shareholders prosperity even in tough times.
There is tremendous potential to profit in oil and gas companies for informed investors. Mr. Schaefer has a degree in journalism but has spent the last 15 years assisting public resource companies in raising exploration and expansion capital.
I joined Seeking Alpha as a Senior Editor in 2012 and currently manage the Energy vertical. I've spent the last 18 years working in publishing, and my experience includes editing scientific/medical journals, personal finance magazines, and several investment websites.
Here at Seeking Alpha we're always looking for new ideas and new authors, so please contact me if you're interested in contributing.
I have more than 10 years experience investing in commodities and hard assets such as gold and silver miners, exploration companies, oil and gas producers, MLPs, and various other sectors.
Former broker, now an independent analyst/writer on Seeking Alpha and founder and editor of the Growth Stock Forum. Focusing on small-cap, mid-cap and biotech stocks. Looking for substantial sales and earnings growth potential and seeking the best risk-adjusted returns from my stock selection. Taking advantage of medium to long-term momentum.
My articles represent my personal opinion and analysis and should not be regarded as investment advice in any way. Readers and subscribers should do their own due diligence and/or consult their financial advisor before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.
Exclusive research: http://seekingalpha.com/author/oneil-trader/research
- MD, MBA (NYU-Stern, Finance specialization). Certificate in financial modeling (Wharton).
**Tipranks doesn't reflect my investment picks accurately since it doesn't pick up my premium service ratings.
- Founder: Vasuda Healthcare Analytics, premium research service covering emerging biotech/ pharma companies (www.research-biotechstocks.com).
- Founder, Trident Asian Research (www.tridentasia.com)
- Investment insights contributor: SumZero, Buy-side Institutional Platform (sumzero.com). Members of the platform include some of the largest hedge funds and asset managers.
-Former Insight Provider for Smartkarma Intelligent Investing (www.smartkarma.com): Institutional Investments Research Platform (was ranked among top 10 out of over 100 contributors). Clients included some of the largest hedge funds and asset managers.
- Buy-side equity research analyst covering mainly small-cap, emerging pharma/ biotech companies. M.D. with over 18 years of clinical experience (in the U.S. and India), still retaining full medical license in India. M.B.A. with finance and financial markets specialization from New York University Stern School of Business.
- Expert in picking healthcare-related investments, especially biotechnology and pharmaceuticals (focus on small, emerging companies). Investments are selected based on detailed due diligence, including proprietary DCF valuation models. Value investor with long-term horizon.
- Founder, managing principal of Vasuda Capital Management, healthcare-focused investment management firm, vasudacapitalmanagement.com. Registered Investment Advisor in Massachusetts.
- Also started and continue to sponsor Vasuda Global Orphan/ Rare disease biotechnology index, the first global equity index covering rare/orphan disease sector. Index quotes are available on bloomberg/reuters terminals.
Individual investor since 2000. I have a natural tendency to question what others take for granted. That's not always a good life skill but it's helped me from time to time in the market.
My degree is in Mechanical Engineering. I also have a background in biochemistry and (oddly enough) in classical Greek literature. My main professional interests are in software, math, and engineering analysis. I've worked in the automotive field, robotics, computer vision and machine learning, and have developed cheminformatics techniques for biotech.
Investment-wise, I tend to be opportunistic rather than systematic. I have a particular interest in volatility trading and in the intersection of technology with societal change.
Dr Jonathan Kinlay is the Head of Quantitative Trading at Systematic Strategies, LLC, a systematic hedge fund that deploys high frequency trading strategies using news-based algorithms.
Dr Kinlay, was the founder and General Partner of the Caissa Capital hedge fund, whose volatility arbitrage strategies were developed by Dr Kinlay’s investment research firm, Investment Analytics. Caissa, which managed $400M in assets, was ranked by FIMAT as the top performing fund in its class in 2004. Dr Kinlay went on to establish the Proteom Capital, whose statistical arbitrage strategies were based on pattern recognition techniques used in DNA sequencing. Dr Kinlay was formerly Global Head of Model Review at the US investment bank Bear Stearns.
Dr Kinlay holds a PhD in economics and has held positions on the faculty at New York University Stern School of Business, Carnegie Mellon and Reading Universities. Dr Kinlay is a regular conference speaker and writer on investment research, hedge fund investing and quantitative finance. Kinlay was a member of England’s chess team that won gold in the World Student Olympiad in Mexico in 1978. He is the son of Fleet Street editor James Kinlay and father of British actress Antonia Kinlay.
Further investment research and strategy ideas can be found in his blog at www.jonathankinlay.com .